End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.86 MYR | +4.24% | +6.17% | -8.51% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company appears to be poorly valued given its net asset value.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Low profitability weakens the company.
- With an expected P/E ratio at 86 and 46.49 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.51% | 445M | C+ | ||
+11.63% | 27.79B | B+ | ||
-31.67% | 2.98B | B- | ||
-14.68% | 2.52B | C+ | ||
+11.64% | 2.34B | - | A- | |
+2.96% | 1.91B | B | ||
-11.65% | 1.83B | - | ||
-1.67% | 1.39B | B | ||
-0.38% | 1.27B | - | ||
+3.58% | 1.13B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SUPERMX Stock
- Ratings Supermax Corporation